Tickers

1. Composite Trajectory Verdict

Given XRAY's capital-intensive manufacturing model with significant goodwill from acquisitions, all three statements carry roughly equal weight: the income statement reveals the sustainability of operations, cash flow shows the ability to fund investments and service debt, and the balance sheet reflects the cumulative impact of impairments and leverage.

Composite Trajectory: Mixed

The earnings trajectory shows recent year-over-year improvement (operating loss narrowed to $(422)M from $(879)M, net loss to $(598)M from $(910)M) but remains materially worse than 2023 (operating loss $(85)M, net loss $(132)M). Cash generation is mixed: operating cash flow fell 49% to $235M, yet net cash rose $54M due to $553M of long-term debt proceeds and no share repurchases. The balance sheet shows improved current liquidity (current assets up 16%, current liabilities down 15%) but deteriorated solvency (total equity down 31% to $1,340M, net debt to capitalization up to 59.9% from 48.9%). Thus, recent operational and liquidity improvements are offset by multi-year earnings decline, operating cash flow erosion, and rising leverage.

2. Red Flags

• Recurring large goodwill/intangible impairments: $307M (2023), $1,014M (2024), $650M (2025) – impairments in three consecutive years totaling $1.97B (10-K 2025-12-31, Consolidated Statements of Operations; Note 11).
• Three consecutive annual net losses: $(132)M (2023), $(910)M (2024), $(598)M (2025) (10-K 2025-12-31, Consolidated Statements of Operations).
• Operating cash flow collapse: dropped to $235M in 2025 from $461M in 2024 and $377M in 2023 (10-K 2025-12-31, Consolidated Statements of Cash Flows).
• Working capital deterioration: days sales outstanding rose to 62 days from 55 days; days inventory rose to 131 days from 124 days (10-K 2025-12-31, MD&A Liquidity and Capital Resources).
• Leverage increase: net debt to total capitalization rose to 59.9% from 48.9%; total equity fell 31% to $1,340M (10-K 2025-12-31, MD&A Liquidity and Capital Resources; Consolidated Balance Sheets).
• Covenant amendment: December 2025 amendments permitted higher leverage ratios (stepping down from 4.25x to 2.50x) and added restricted payment restrictions (10-K 2025-12-31, Note 14).
• Valuation allowance surge: deferred tax asset valuation allowance grew to $2,103M from $1,503M (10-K 2025-12-31, Note 16).
• Dividend elimination: Board eliminated quarterly dividends starting Q1 2026 (10-K 2025-12-31, MD&A Liquidity and Capital Resources).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Mixed

Overall Assessment: Net sales declined 3.0% to $3,680M in 2025 from $3,793M in 2024 (and 7.2% from $3,965M in 2023) (10-K 2025-12-31, Consolidated Statements of Operations). Gross margin compressed 160 bps to 50.0% (10-K 2025-12-31, MD&A Gross Profit). Operating loss narrowed to $(422)M from $(879)M in 2024 but remained far above the $(85)M loss in 2023 (10-K 2025-12-31, Consolidated Statements of Operations). Net loss improved to $(598)M from $(910)M but was still 4.5x the 2023 loss of $(132)M (10-K 2025-12-31, Consolidated Statements of Operations). Goodwill and intangible impairments remained elevated at $650M (10-K 2025-12-31, Consolidated Statements of Operations). SG&A fell 10.4% to $1,438M (10-K 2025-12-31, MD&A Operating Expenses). The 2025 results represent a year-over-year improvement but a clear multi-year deterioration from 2023 levels.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Mixed

Overall Assessment: Net cash provided by operating activities fell sharply to $235M in 2025 from $461M in 2024 and $377M in 2023 (10-K 2025-12-31, Consolidated Statements of Cash Flows). Capital expenditures decreased to $131M from $180M (10-K 2025-12-31, Consolidated Statements of Cash Flows), yielding free cash flow (operating minus capex) of $104M vs $281M in 2024. Net cash used in financing activities improved to $(80)M from $(302)M, driven by $553M of long-term debt proceeds and zero share repurchases (vs $250M in 2024) (10-K 2025-12-31, Consolidated Statements of Cash Flows). Net cash increased $54M in 2025 after a $62M decrease in 2024 (10-K 2025-12-31, Consolidated Statements of Cash Flows). Operating cash generation deteriorated materially, but overall liquidity was bolstered by financing activities.

5. Balance Sheet Assessment

Balance Sheet Trajectory: Mixed

Overall Assessment: Total assets declined to $5,429M from $5,753M (10-K 2025-12-31, Consolidated Balance Sheets). Goodwill dropped 28% to $1,148M from $1,597M due to impairments (10-K 2025-12-31, Consolidated Balance Sheets; Note 11). Identifiable intangible assets fell 19% to $974M from $1,207M (10-K 2025-12-31, Consolidated Balance Sheets). Current assets rose 16% to $2,023M (receivables +$132M to $688M, inventory +$78M to $642M) (10-K 2025-12-31, Consolidated Balance Sheets). Current liabilities fell 15% to $1,343M (10-K 2025-12-31, Consolidated Balance Sheets). Long-term debt increased 27% to $2,015M from $1,586M (10-K 2025-12-31, Consolidated Balance Sheets). Total equity declined 31% to $1,340M from $1,943M (10-K 2025-12-31, Consolidated Balance Sheets). Net debt to total capitalization rose to 59.9% from 48.9% (10-K 2025-12-31, MD&A Liquidity and Capital Resources). Liquidity improved (current ratio strengthened), but solvency weakened significantly.

6. Data Gaps

• Quarterly GAAP income statement, cash flow, and balance sheet data for Q1 2025, Q3 2024, Q4 2024 to enable quarter-over-quarter trend analysis (only Q2 2025 and Q2 2026 10-Qs are referenced but not fully provided).
• Segment-level GAAP operating income (only non-GAAP "segment adjusted operating income" is disclosed in Note 6).
• Full 2023 balance sheet (only 2024 and 2025 presented in the 10-K) to assess three-year balance sheet trends.
• Breakdown of "Other noncurrent liabilities" increase from $415M to $544M (10-K 2025-12-31, Consolidated Balance Sheets) – nature not detailed in provided notes.
• Cash flow impact of the 2026 restructuring plan (approved February 2026, charges expected 2026-2027) (10-K 2025-12-31, MD&A Material Trends in Capital Resources).